Association of dynamic susceptibility contrast- and dynamic contrast-enhanced magnetic resonance imaging parameters with molecular marker status in lower-grade gliomas: A retrospective study
Restricted accessResearch articleFirst published online February, 2023
Association of dynamic susceptibility contrast- and dynamic contrast-enhanced magnetic resonance imaging parameters with molecular marker status in lower-grade gliomas: A retrospective study
Molecular marker status is clinically relevant for treatment planning and predicting the prognosis of gliomas. This study aimed to assess whether quantitative imaging parameters from dynamic susceptibility contrast- (DSC-) and dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) can predict the molecular marker status of lower-grade gliomas (LGGs).
Materials and methods
Overall, 132 patients with LGGs who underwent DSC- and DCE-MRI were retrospectively enrolled. Statuses of relevant molecular markers including isocitrate dehydrogenase isoenzyme (IDH), 1p19q codeletion, epidermal growth factor receptor (EGFR), O6-methylguanine-DNA methyltransferase (MGMT), and telomerase reverse transcriptase (TERT) were collected. For each molecular marker, age, tumor diameter and location, and DSC- and DCE-MRI parameters, including the normalized cerebral blood volume (nCBV), volume transfer constant (Ktrans), rate transfer coefficient (Kep), extravascular extracellular volume fraction (Ve), and plasma volume fraction (Vp), were compared. Multivariable logistic regression analyses were performed.
Results
The nCBV was significantly lower in LGGs with IDH mutation (p = .001) and TERT mutation (p = .027) than those without these mutations. Ktrans (p = .034), Ve (p = .023), and Vp (p = .044) values were significantly lower in MGMT methylated LGGs than in MGMT unmethylated LGGs. Perfusion parameters were not significantly associated with EGFR amplification and 1p19q codeletion. Young age (p < .001) and small diameter (p = .001) were significantly associated with IDH mutation. The nCBV was independently associated with IDH status (AUC, 0.817; 95% CI: 0.739–0.894).
Conclusions
DSC- and DCE-MRI parameters demonstrated correlations with molecular markers of LGGs. Especially, the nCBV can be helpful in predicting the IDH mutation status.
LouisDNPerryAReifenbergerG, et al.The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol2016; 131: 803–820. DOI: 10.1007/s00401-016-1545-1
HuseJTDiamondELWangL, et al.Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma. Acta Neuropathol2015; 129: 151–153. DOI: 10.1007/s00401-014-1359-y
4.
AquilantiEMillerJSantagataS, et al.Updates in prognostic markers for gliomas. Neuro Oncol2018; 20(7): vii17–vii26. DOI: 10.1093/neuonc/noy158
5.
BratDJAldapeKDSalamaSR, et al.Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med2015; 372: 2481–2498. DOI: 10.1056/NEJMoa1402121
6.
LouisDNAldapeKBratDJ, et al.cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol2017; 27: 851–852. DOI: 10.1111/bpa.12457
7.
LouisDNAldapeKBratDJ, et al.Announcing cIMPACT-NOW: the consortium to inform molecular and practical approaches to CNS tumor taxonomy. Acta Neuropathol2017; 133: 1–3. DOI: 10.1007/s00401-016-1646-x
8.
BratDJAldapeKColmanH, et al.cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV. Acta Neuropathol2018; 136: 805–810. DOI: 10.1007/s00401-018-1913-0
9.
ZhangJLiuHTongH, et al.Clinical applications of contrast-enhanced perfusion MRI techniques in gliomas: recent advances and current challenges. Contrast Media Mol Imaging2017; 2017: 1–27. DOI: 10.1155/2017/7064120
10.
LiangJLiuDGaoP, et al.Diagnostic values of DCE-MRI and DSC-MRI for differentiation between high-grade and low-grade gliomas: a comprehensive meta-analysis. Acad Radiol2018; 25: 338–348. DOI: 10.1016/j.acra.2017.10.001
11.
ZhangH-WlyuG-WHeW-J, et al.DSC and DCE histogram analyses of glioma biomarkers, including IDH, MGMT, and TERT, on differentiation and survival. Acad Radiol2020; 27: e263–e271. DOI: 10.1016/j.acra.2019.12.010
12.
BhandariAPLiongRKoppenJ, et al.Noninvasive determination of IDH and 1p19q status of lower-grade gliomas using MRI radiomics: a systematic review. AJNR Am J Neuroradiol2021; 42: 94–101. DOI: 10.3174/ajnr.A6875
13.
AhnSSShinN-YChangJH, et al.Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging. J Neurosurg2014; 121: 367–373. DOI: 10.3171/2014.5.JNS132279
14.
LinYXingZSheD, et al.IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRI. Neuroradiology2017; 59: 555–562. DOI: 10.1007/s00234-017-1839-6
15.
YanHParsonsDWJinG, et al.IDH1 and IDH2 mutations in gliomas. N Engl J Med2009; 360: 765–773. DOI: 10.1056/NEJMoa0808710
16.
RiemenschneiderMJJeukenJWWesselingP, et al.Molecular diagnostics of gliomas: state of the art. Acta Neuropathol2010; 120: 567–584. DOI: 10.1007/s00401-010-0736-4
17.
NaKKimH-SShimHS, et al.Targeted next-generation sequencing panel (TruSight tumor 170) in diffuse glioma: a single institutional experience of 135 cases. J Neurooncol2019; 142: 445–454. DOI: 10.1007/s11060-019-03114-1
18.
VlassenbroeckICalificeSDiserensA-C, et al.Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn2008; 10: 332–337. DOI: 10.2353/jmoldx.2008.070169
19.
WeisskoffRMBoxermanJLSorensenAG, et al.Simultaneous blood volume and permeability mapping using a single Gd=based contrast injection. In Proceedings of the Society of Magnetic Resonance, Second Annual Meeting, 1994 Aug 6 (pp. 6–12).
20.
BoxermanJLSchmaindaKMWeisskoffRM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol2006; 27: 859–867.
21.
ToftsPSBrixGBuckleyDL, et al.Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging1999; 10: 223–232. DOI: 10.1002/(sici)1522-2586(199909)10:3<223::aid-jmri2>3.0.co;2-s
22.
ParkYWHanKAhnSS, et al.Prediction of IDH1-mutation and 1p/19q-codeletion status using preoperative MR imaging phenotypes in lower grade gliomas. AJNR Am J Neuroradiol2018; 39: 37–42. DOI: 10.3174/ajnr.A5421
23.
KickingerederPSahmFRadbruchA, et al.IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep2015; 5: 16238. DOI: 10.1038/srep16238
24.
TykocinskiESGrantRAKapoorGS, et al.Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro Oncol2012; 14: 613–623. DOI: 10.1093/neuonc/nos073
25.
GuptaAYoungRJShahAD, et al.Pretreatment dynamic susceptibility contrast MRI perfusion in glioblastoma: prediction of EGFR gene amplification. Clin Neuroradiol2015; 25: 143–150. DOI: 10.1007/s00062-014-0289-3
26.
MoonWJChoiJWRohHG, et al.Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. Neuroradiology2012; 54: 555–563. DOI: 10.1007/s00234-011-0947-y
27.
HanSLiuYCaiSJ, et al.IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer2020; 122: 1580–1589. DOI: 10.1038/s41416-020-0814-x
28.
MausAPetersGJ. Glutamate and alpha-ketoglutarate: key players in glioma metabolism. Amino Acids2017; 49: 21–32. DOI: 10.1007/s00726-016-2342-9
29.
XingZYangXSheD, et al.Noninvasive assessment of IDH mutational status in world health organization grade II and III astrocytomas using DWI and DSC-PWI combined with conventional MR imaging. AJNR Am J Neuroradiol2017; 38: 1138–1144. DOI: 10.3174/ajnr.A5171
30.
MetellusPCoulibalyBColinC, et al.Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol2010; 120: 719–729. DOI: 10.1007/s00401-010-0777-8
31.
BeikoJSukiDHessKR, et al.IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol2014; 16: 81–91. DOI: 10.1093/neuonc/not159
32.
LiuYJiangWLiuJ, et al.IDH1 mutations inhibit multiple alpha-ketoglutarate-dependent dioxygenase activities in astroglioma. J Neurooncol2012; 109: 253–260. DOI: 10.1007/s11060-012-0914-4
33.
HempelJ-MSchittenhelmJKloseU, et al.In Vivo molecular profiling of human glioma: cross-sectional observational study using dynamic susceptibility contrast magnetic resonance perfusion imaging. Clin Neuroradiol2019; 29: 479–491. DOI: 10.1007/s00062-018-0676-2
34.
CairncrossGWangMShawE, et al.Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol2013; 31: 337–343. DOI: 10.1200/JCO.2012.43.2674
35.
EmblemKEScheieDDue-TonnessenP, et al.Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes. AJNR Am J Neuroradiol2008; 29: 1664–1670. DOI: 10.3174/ajnr.A1182
36.
JenkinsonMDSmithTSJoyceKA, et al.Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology2006; 48: 703–713. DOI: 10.1007/s00234-006-0122-z
37.
KimJWParkC-KParkS-H, et al.Relationship between radiological characteristics and combined 1p and 19q deletion in world health organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry2011; 82: 224–227. DOI: 10.1136/jnnp.2009.178806
38.
FellahSCaudalDDe PaulaAM, et al.Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?AJNR Am J Neuroradiol2013; 34: 1326–1333. DOI: 10.3174/ajnr.A3352
ChoiJKimSHAhnSS, et al.Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma. Sci Rep2020; 10: 2086. DOI: 10.1038/s41598-020-59089-x
41.
TanriverdiTKemerdereRBaranO, et al.Long-term surgical and seizure outcomes of frontal low-grade gliomas. Int J Surg2016; 33: 60–64. DOI: 10.1016/j.ijsu.2016.07.065
42.
ParkYWAhnSSParkCJ, et al.Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas. Eur Radiol2020; 30: 6475–6484. DOI: 10.1007/s00330-020-07090-3
43.
StichelDEbrahimiAReussD, et al.Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol2018; 136: 793–803. DOI: 10.1007/s00401-018-1905-0
44.
ShinojimaNTadaKShiraishiS, et al.Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res2003; 63: 6962–6970.
45.
BarkerFGChangMLSMPradosMD, et al.EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys2001; 51: 410–418. DOI: 10.1016/s0360-3016(01)01609-1
46.
ZadehGBhatKPAldapeK. EGFR and EGFRvIII in glioblastoma: partners in crime. Cancer Cell2013; 24: 403–404. DOI: 10.1016/j.ccr.2013.09.017
47.
Arevalo-PerezJThomasAAKaleyT, et al.T1-weighted dynamic contrast-enhanced MRI as a noninvasive biomarker of epidermal growth factor receptor vIII status. AJNR Am J Neuroradiol2015; 36: 2256–2261. DOI: 10.3174/ajnr.A4484
48.
ChahalMXuYLesniakD, et al.MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol2010; 12: 822–833. DOI: 10.1093/neuonc/noq017
49.
RyooIChoiSHKimJ-H, et al.Cerebral blood volume calculated by dynamic susceptibility contrast-enhanced perfusion MR imaging: preliminary correlation study with glioblastoma genetic profiles. PLoS One2013; 8: e71704. DOI: 10.1371/journal.pone.0071704
50.
LabussiereMDi StefanoALGleizeV, et al.TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer2014; 111: 2024–2032. DOI: 10.1038/bjc.2014.538
51.
HeidenreichBRachakondaPSHemminkiK, et al.TERT promoter mutations in cancer development. Curr Opin Genet Dev2014; 24: 30–37. DOI: 10.1016/j.gde.2013.11.005
52.
LowKCTergaonkarV. Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci2013; 38: 426–434. DOI: 10.1016/j.tibs.2013.07.001
53.
MaiaACJr.MalheirosSMDa RochaAJ, et al.MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol2005; 26: 777–783
54.
LawMYangSBabbJS, et al.Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol2004; 25: 746–755
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
